Phaseline

Targets › ANGPT2

ANGPT2 (Angiopoietin-2): drug programs, companies and trials

3 programs from 2 companies in 15 trials: 9 Phase 4, 5 Phase 3, 1 Phase 2; Ophthalmology, Oncology; next expected readout Jan 2027.

Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling. Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. (UniProt, O15123)

Open in Phaseline: the race on ANGPT2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheFaricimab
Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor
ANGPT2, VEGFAPhase 4Diabetic Macular EdemaJan 2027
RocheFaricimab
Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor
ANGPT2, VEGFAPhase 4Neovascular Age-related Macular Degeneration (nAMD); Wet Age-related Macular Degeneration; Diabetic Macular Edema; Macular Degeneration Choroidal Neovascularization …Sep 2027
Anhui Provincial HospitalIvonescimab
ANGPT2 inhibitor, anti-angiogenic monoclonal antibody
ANGPT2Phase 2Esophageal Squamous Cell CarcinomaJun 2027

Conditions

Diabetic Macular Edema (2) Esophageal Squamous Cell Carcinoma (1) Neovascular Age-related Macular Degeneration (nAMD) (1) Wet Age-related Macular Degeneration (1) Macular Degeneration Choroidal Neovascularization (1) Macular Degeneration (1) Presumed Ocular Histoplasmosis (1) Polypoidal Choroidal Vasculopathy (1) Macular Degeneration, Age Related (1) Neovascular Age-related Macular Degeneration (1) Polypoidal Choroidal Vasculopathy (PCV) (1) Severe Diabetic Macular Oedema (1)

Modalities

antibody (3)

Companies

Roche (2) Anhui Provincial Hospital (1)

Related targets

VEGFA (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.